Thanks @keatz for your reply and efforts. You are right, many of us have been part of a patient group of shareholders. Hopefully we get justly rewarded soon. GLALTHs AIMHO
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling